Combined use of the high heparin step and optical density to optimize diagnostic sensitivity and specificity of an anti-PF4/heparin enzyme-immunoassay

被引:30
作者
Althaus, Karina [1 ]
Strobel, Ulrike [1 ]
Warkentin, Theodore E. [2 ]
Greinacher, Andreas [1 ]
机构
[1] Ernst Moritz Arndt Univ Greifswald, Inst Immunol & Transfus Med, D-17489 Greifswald, Germany
[2] McMaster Univ, Dept Pathol & Mol Med, Hamilton, ON, Canada
关键词
Heparin-induced thrombocytopenia; HIT; laboratory testing; heparin; PF4; INDUCED THROMBOCYTOPENIA; CONFIRMATORY PROCEDURE; CARDIOPULMONARY BYPASS; UNFRACTIONATED HEPARIN; CLINICAL-SIGNIFICANCE; INDUCED ANTIBODIES; RISK-FACTORS; VALUES; IGG; PLATELET-FACTOR-4;
D O I
10.1016/j.thromres.2011.05.003
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: IgG-specific anti-PF4/heparin enzyme-immunoassays (EIAs) are sensitive but not specific for platelet-activating antibodies, the cause of heparin-induced thrombocytopenia (HIT). Two features of EIA reactivity predict for presence of HIT antibodies - the magnitude of a positive result (in optical density [OD] units) and the inhibition of reactivity at high heparin concentrations - but their combined utility remains uncertain. Objective: To determine for an IgG-specific EIA how the OD values of a positive reaction and its inhibition by high heparin can be optimally combined. Methods: We screened 1,000 consecutive patients with suspected HIT using an IgG-specific PF4/heparin in-house EIA with and without high heparin (100 IU/mL); and by the heparin-induced platelet activation test. Results: Platelet-activating antibodies were rarely detected (<0.2%) when the IgG-specific EIA was negative at the conventional cut-off (OD, 0.5). However, an OD cut-off of 1.0 resulted in an unacceptable loss of sensitivity (14/83 = 17%) for detecting platelet-activating antibodies. The high heparin step increased specificity for platelet-activating antibodies from 72% to 89% without loss of sensitivity when applied to weak-positive sera (OD <= 1.0). However, decreased sensitivity was observed with strong-positive sera (OD > 1.0): 11/69 such sera (16%) that did not show >40% inhibition by high heparin nevertheless contained platelet-activating antibodies. Conclusion: Specificity of an IgG-specific EIA for detecting platelet-activating antibodies can be optimized by applying the high heparin inhibition step to weak-positive reactions (0.5- <= 1.0 OD). However, applying the high heparin inhibition step to strong-positive reactions (>1.0 OD) in our in-house assay risks falsely classifying a serum as negative for platelet-activating antibodies. (C) 2011 Elsevier Ltd. All rights reserved.
引用
收藏
页码:256 / 260
页数:5
相关论文
共 33 条
[1]  
AMIRAL J, 1992, THROMB HAEMOSTASIS, V68, P95
[2]  
[Anonymous], HEPARIN INDUCED THRO
[3]   Prospective evaluation of PF4/heparin immunoassays for the diagnosis of heparin-induced thrombocytopenia [J].
Bakchoul, T. ;
Giptner, A. ;
Najaoui, A. ;
Bein, G. ;
Santoso, S. ;
Sachs, U. J. H. .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 (08) :1260-1265
[4]   Performance characteristics of two commercially available IgG-specific immunoassays in the assessment of heparin-induced thrombocytopenia (HIT) [J].
Bakchoul, Tamam ;
Giptner, Astrid ;
Bein, Gregor ;
Santoso, Sentot ;
Sachs, Ulrich J. H. .
THROMBOSIS RESEARCH, 2011, 127 (04) :345-348
[5]   Thrombocytopenia in medical-surgical critically ill patients: prevalence, incidence, and risk factors [J].
Crowther, MA ;
Cook, DJ ;
Meade, MO ;
Griffith, LE ;
Guyatt, GH ;
Arnold, DM ;
Rabbat, CG ;
Geerts, WH ;
Warkentin, TE .
JOURNAL OF CRITICAL CARE, 2005, 20 (04) :348-353
[6]   The new ID-heparin/PF4: antibody test for rapid detection of heparin-induced antibodies in comparison with functional and antigenic assays [J].
Eichler, P ;
Raschke, R ;
Lubenow, N ;
Meyer, O ;
Schwind, P ;
Greinacher, A .
BRITISH JOURNAL OF HAEMATOLOGY, 2002, 116 (04) :887-891
[7]   Heparin-induced thrombocytopenia: a prospective study on the incidence, platelet-activating capacity and clinical significance of antiplatelet factor 4/heparin antibodies of the IgG, IgM, and IgA classes [J].
Greinacher, A. ;
Juhl, D. ;
Strobel, U. ;
Wessel, A. ;
Lubenow, N. ;
Selleng, K. ;
Eichler, P. ;
Warkentin, T. E. .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2007, 5 (08) :1666-1673
[8]   Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis [J].
Greinacher, A ;
Farner, B ;
Kroll, H ;
Kohlmann, T ;
Warkentin, TE ;
Eichler, P .
THROMBOSIS AND HAEMOSTASIS, 2005, 94 (01) :132-135
[9]   Heparin-induced thrombocytopenia: towards standardization of platelet factor 4/heparin antigen tests [J].
Greinacher, A. ;
Ittermann, T. ;
Bagemuehl, J. ;
Althaus, K. ;
Fuerll, B. ;
Selleng, S. ;
Lubenow, N. ;
Schellong, S. ;
Sheppard, J. I. ;
Warkentin, T. E. .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2010, 8 (09) :2025-2031
[10]  
GREINACHER A, 1992, THROMB HAEMOSTASIS, V67, P545